Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

News release details

Blueprint Medicines to Report Updated Data from the Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis on Monday, March 16, 2020

March 9, 2020 at 9:00 AM EDT
-- Plan to report data on investor conference call and webcast on March 16 at 7:30 a.m. ET, following cancellation of 2020 AAAAI Annual Meeting --

CAMBRIDGE, Mass., March 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reaffirmed previously announced plans to host a live conference call and webcast on Monday, March 16, 2020 to report updated data from Part 1 of the Phase 2 PIONEER trial of avapritinib in patients with indolent systemic mastocytosis, following the cancellation of the 2020 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

Blueprint Medicines previously announced plans to present a late-breaking oral abstract on the PIONEER trial data at the 2020 AAAAI Annual Meeting. Due to the cancellation of the AAAAI Annual Meeting, Blueprint Medicines now plans to report the data during the investor conference call and webcast on March 16, 2020 at 7:30 a.m. ET.

Conference Call Information

To access the live call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international) and refer to conference ID 1590639. A webcast of the conference call will be available in the Investors & Media section of Blueprint Medicines' website at The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have one precision therapy approved by the U.S. Food and Drug Administration and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs. For more information, visit and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:

SOURCE Blueprint Medicines Corporation

Investor Relations Contact - Kristin Hodous, 617-714-6674,; Media Relations Contact - Andrew Law, 617-844-8205,